Alosetron
Alosetron, Lotronex (alosetron) is a small molecule pharmaceutical. Alosetron was first approved as Lotronex on 2000-02-09. It is used to treat abdominal pain, diarrhea, and irritable bowel syndrome in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Alosetron, Lotronex (discontinued: Alosetron)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alosetron hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOTRONEX | Sebela Pharmaceuticals | N-021107 RX | 2000-02-09 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alosetron | ANDA | 2024-01-11 |
| alosetron hydrochloride | ANDA | 2023-03-26 |
| alosetron hyochloride | ANDA | 2019-02-12 |
| lotronex | New Drug Application | 2019-05-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| irritable bowel syndrome | EFO_0000555 | D043183 | K58 |
| diarrhea | HP_0002014 | D003967 | R19.7 |
| abdominal pain | HP_0002027 | D015746 | R10.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | 2 | 1 | 1 | 5 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alosetron |
| INN | alosetron |
| Description | Alosetron is a pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position. It has a role as a serotonergic antagonist, an antiemetic and a gastrointestinal drug. It is a pyridoindole and a member of imidazoles. |
| Classification | Small molecule |
| Drug class | serotonin 5-HT3 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 122852-42-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1110 |
| ChEBI ID | 253342 |
| PubChem CID | 2099 |
| DrugBank | DB00969 |
| UNII ID | 13Z9HTH115 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Alosetron
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,040 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alosetron, Alosetron hydrochloride, Alosetron hyochloride, Lotronex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
809 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use